NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

Journal Article (Journal Article)

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).

Full Text

Duke Authors

Cited Authors

  • Mehta-Shah, N; Horwitz, SM; Ansell, S; Ai, WZ; Barnes, J; Barta, SK; Clemens, MW; Dogan, A; Fisher, K; Goodman, AM; Goyal, G; Guitart, J; Halwani, A; Haverkos, BM; Hoppe, RT; Jacobsen, E; Jagadeesh, D; Lunning, MA; Mehta, A; Olsen, EA; Pro, B; Rajguru, SA; Shanbhag, S; Shaver, A; Shustov, A; Sokol, L; Torka, P; Torres-Cabala, C; Wilcox, R; William, BM; Zain, J; Dwyer, MA; Sundar, H; Kim, YH

Published Date

  • May 2020

Published In

Volume / Issue

  • 18 / 5

Start / End Page

  • 522 - 536

PubMed ID

  • 32380458

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2020.0022


  • eng

Conference Location

  • United States